We propose that this gene variant should be further validated and replicated in larger sample groups, and most of all, we propose a deeper investigation of the mechanisms by which EGLN2, an oxygen sensor and critical regulator of the response to hypoxia, could affect neurological deficit and disability in MS. Here, EGLN2 is linked to myeloid sarcoma.